Main Uses of L-Thyroxin Henning 75

L-Thyroxin Henning 75 is a hormone replacement therapy primarily used to manage conditions related to thyroid gland dysfunction. It contains levothyroxine sodium, a synthetic version of the naturally occurring thyroid hormone thyroxine (T4). This medication is typically prescribed for the following indications:

Thyroid Hormone Replacement

The primary use of L-Thyroxin Henning 75 is to replace thyroid hormones in patients whose thyroid glands do not produce sufficient amounts on their own. This condition, known as hypothyroidism, can result from various causes, including autoimmune disorders, surgical removal of the thyroid, or radiation therapy.

Prevention of Goiter

This medication is used to prevent the formation or recurrence of a goiter, which is an abnormal enlargement of the thyroid gland. By providing a steady supply of external thyroid hormones, the medication helps reduce the secretion of thyroid-stimulating hormone (TSH), thereby decreasing the stimulus for the gland to grow.

Management of Thyroid Tumors

In patients with thyroid-related tumors, L-Thyroxin Henning 75 may be used as part of a therapeutic regimen to suppress TSH levels. This suppression is often a critical component of managing certain types of thyroid cancer or benign nodules, as it helps inhibit the growth of hormone-sensitive tissues.

Concomitant Therapy for Hyperthyroidism

In specific clinical scenarios where patients are receiving antithyroid medications for an overactive thyroid (hyperthyroidism), L-Thyroxin Henning 75 may be prescribed simultaneously. This "block-and-replace" approach helps maintain a stable metabolic state and prevents the development of hypothyroidism during treatment.

---

Benefits of Treatment

The primary benefit of L-Thyroxin Henning 75 is the restoration of normal metabolic function. Because thyroid hormones influence nearly every organ system in the body, effective treatment helps stabilize several physiological processes:

• Metabolic Regulation: Normalization of the basal metabolic rate, which can assist in stabilizing energy levels and body temperature.
• Organ Function: Support for healthy heart rate, digestive processes, and muscle function.
• Mental Clarity: Improvement in cognitive functions such as concentration and memory, which are often affected by hormone deficiencies.
• Growth and Development: In specific populations, the medication ensures that necessary hormonal levels are present for proper physical and neurological development.

Regulatory References

1. Health Products Regulatory Authority Product Information

Eligibility Map: Who can and cannot use L-Thyroxin Henning 75 — Official Regulatory Information

The eligibility for L-Thyroxin Henning 75 is strictly governed by regulatory documentation, which outlines absolute prohibitions and conditions requiring restricted use.

---

Eligibility Classification	Populations / Conditions
Absolutely Contraindicated (Must Not Use)	Untreated overt thyrotoxicosis; acute myocardial infarction or acute carditis; uncorrected adrenal insufficiency; known hypersensitivity to the drug or its components.
Established Use (Permitted)	Adults and Children requiring thyroid hormone replacement; Pregnant Women (treatment must be continued/initiated); Lactating Women (minimal risk documented).

---

Age-Related & Restricted Use	Regulatory Requirement
Geriatric Use (Older Adults)	Use is permitted but restricted to a low initial dose due to the increased risk of cardiac side effects.
Cardiovascular Disease	Patients with conditions like Coronary Heart Disease must start treatment at a lower dose than standard replacement and be closely monitored.

---

Use Prohibited by Warning: The medicine is explicitly not indicated for the treatment of obesity or weight loss in patients with normal thyroid function, and is prohibited from being used to suppress benign thyroid nodules in iodine-sufficient patients.

Interactions with other medicines and products

The interaction profile for levothyroxine sodium is defined by officially documented patterns involving changes to its absorption, metabolism, and the resulting effects on co-administered medicines, as stated by government regulatory authorities.

Documented Interaction Restrictions

Classification	Interacting Substance/Condition	Regulatory Statement
Contraindicated Combination	Sympathomimetic Amines (for weight loss)	Prohibited due to the risk of serious or life-threatening toxicity.
Population Caution	Patients with Uncorrected Adrenal Insufficiency	Therapy may precipitate an acute adrenal crisis and requires pre-treatment.

---

Pharmacokinetic and Pharmacodynamic Effects

Levothyroxine absorption is reduced by various substances, including Antacids (aluminum/magnesium), Calcium Salts, Oral Iron, and certain Bile Acid Sequestrants (like Cholestyramine and Sucralfate). Regulatory labeling mandates that levothyroxine must be administered at least 4 hours apart from these binding agents. Co-administration with Proton Pump Inhibitors (PPIs) may also decrease absorption.

Conversely, several medicines and products are documented to accelerate the metabolism of levothyroxine, leading to reduced plasma concentrations. These include anti-convulsants such as Phenytoin and Carbamazepine, as well as the herbal product St John's Wort.

Pharmacodynamically, levothyroxine increases the effect of Oral Anticoagulants (e.g., Warfarin) and may also raise blood sugar levels, requiring careful regulatory attention if co-administered with Hypoglycaemic Agents. The supplement Biotin is also documented to interfere with thyroid blood tests, leading to falsely decreased or increased results.

Prohormone Conversion and Activation

L-Thyroxin Henning 75 provides Levothyroxine (T4), a synthetic prohormone, to the body. Following systemic absorption, T4 is actively transported into target cells. Inside the cell, T4 must be enzymatically converted into the biologically active hormone, triiodothyronine (T3), primarily by deiodinase enzymes. This localized conversion process is required to generate the active signaling molecule that influences cellular function.

Nuclear Receptor Binding and Genomic Modulation

The active T3 targets its main biological receptors, the Thyroid Hormone Receptors (TRs), located within the cell nucleus. T3 binding initiates a genomic mechanism by modulating the transcription of specific genes. This action alters the resulting production of key cellular proteins, which modulates processes such as cellular metabolism and energy expenditure across various body systems.

Endocrine Feedback Loop Regulation

As a replacement for the natural hormone, the drug provides negative feedback that acts upon the body's Hypothalamic-Pituitary-Thyroid (HPT) axis through a regulatory mechanism. The circulating levels of T4 and T3 signal to the pituitary gland, leading to the suppression of TSH release. This action influences the regulatory dynamics of the HPT axis, affecting systemic metabolic parameters.

Official Administration Guidelines

The following details describe the standard administration of levothyroxine sodium tablets.

---

Administration Scope

Instruction	Details
Route of administration	The tablet formulation is for oral use. The intravenous route is reserved for acute, non-oral scenarios using other specific formulations.
Dosing schedule	Initial Doses: Starting regimens vary by patient; healthy adults often begin with approximately 1.6 mu g/ kg daily. In older adults or those with pre-existing cardiac conditions, the starting dose is lower, typically 12.5 mu g to 25 mu g daily. Maintenance Range: Full replacement doses typically fall between 100 mu g and 200 mu g per day.
Timing in relation to meals	The medication must be taken once daily on an empty stomach, optimally 30 to 60 minutes before the first meal, to ensure optimal absorption.
Preparation requirements	The tablet may be crushed and suspended in a small volume of water for immediate use by patients unable to swallow it whole; the suspension must not be stored.
Age-group administration rules	Dose adjustments for older adults are implemented more slowly, over intervals of 6 to 8 weeks. Infant dosing is weight-based, starting higher (10 to 15 mu g/ kg/ day) and decreasing as the child ages.
Special procedural conditions	To prevent reduced absorption, the drug must be administered at least 4 hours before or after the intake of specific agents, including iron or calcium supplements and antacids.

---

Course Duration and Titration Protocol

Treatment for hypothyroidism is generally a lifelong regimen. Dose adjustments (titration) are typically made in small increments of 12.5 mu g to 25 mu g every four to six weeks, reflecting the time required for the active substance to reach a steady state after a dose change.

Research Evidence / Overview of Studies for L-Thyroxin Henning 75

The research base for L-Thyroxin Henning 75 (levothyroxine sodium) is summarized here using evidence from official regulatory sources and peer-reviewed scientific literature. This information focuses on describing the existing research and its findings without providing clinical advice, instruction, or details on safety.

---

Evidence for Use in Overt Hypothyroidism

Research has focused on studies of replacement therapy when the thyroid gland is underactive. Because levothyroxine is the established therapy, ethical considerations limit large, placebo-controlled trials in individuals with newly diagnosed, overt thyroid deficiency. The existing structure of evidence is primarily supported by systematic reviews and extensive population-based cohort studies.

Research has monitored the stability of key thyroid hormone biomarkers, including TSH and Free T4, examining the proportion of patients whose measurements aligned with established reference ranges. Studies also included patient experience measures such as quality of life (QoL) scores. Research continues to explore the extent to which biomarker normalization aligns with the measurement of improvement across all patient-reported outcomes.

---

Research into Subclinical Hypothyroidism (SCH)

The role of levothyroxine in individuals with subclinical hypothyroidism (mildly elevated TSH with normal T4) has been studied using Randomized Controlled Trials (RCTs). Studies monitored patient-reported outcomes related to physical discomfort (like fatigue) and examined markers of cardiovascular function.

Findings related to symptom scores and quality of life have been heterogeneous across different study groups. The evidence supporting symptomatic benefit in certain populations, such as older adults with milder degrees of SCH, remains inconsistent, with some trials reporting measurements similar to placebo groups.

---

Evidence Gaps and Research Focus Areas

Research has also been studied for findings in individuals with benign euthyroid goiter, where trials have measured physical changes (goiter volume) and TSH suppression levels. Findings have described patterns related to goiter volume reduction, though the degree of reported change has varied.

Dedicated research has examined outcomes in special populations, including older adults and pregnant individuals. Data for certain groups remain insufficient, and the evidence quality varies across studies. Long-term effects on hard endpoints, such as reduced cardiovascular events, particularly in the context of subclinical disease, are not fully established.

Key Studies & References L-Thyroxin Henning 75 Product Information (Irish Health Products Regulatory Authority)

Common questions about L-Thyroxin Henning 75 (FAQ)

---

Q: Does taking L-Thyroxin Henning 75 affect my ability to drive or operate machinery?

According to the official product information, taking this medicine generally has no or negligible influence on the ability to drive or use machines. No specific studies have been performed to assess this effect. Therefore, for most individuals, regulatory information suggests there is no impact on performing these activities.

---

Q: What is the typical starting dose of L-Thyroxin Henning 75 for hypothyroidism?

The regulatory documents state that treatment for hypothyroidism (underactive thyroid) typically begins with a very low initial dose, which is then increased slowly. The specific starting dose must be established by the treating physician. The overall goal is to reach a stable maintenance dose that is appropriate for the individual patient.

---

Q: Can I take L-Thyroxin Henning 75 if I have coexisting heart conditions?

The official product information specifies that caution is required if certain existing heart conditions are present, such as angina pectoris (chest pain), myocardial infarction (heart attack), or myocarditis (heart muscle inflammation). The medicine should be used with particular care in these situations. The prescribing physician may need to closely monitor thyroid levels and heart function in this circumstance.

---

Q: Is it safe to take L-Thyroxin Henning 75 during pregnancy?

Studies and official information indicate that continued treatment with thyroid hormones during pregnancy is particularly important. Levothyroxine (the active ingredient) does not appear to have harmful effects on the fetus. However, dose adjustments may be necessary, as the requirement for the hormone may increase during pregnancy.

---

Q: What happens if I forget to take my L-Thyroxin Henning 75 dose?

Official product information advises against taking a double dose to compensate for a missed one. It states that the regular prescribed dose should be continued at the next scheduled time. Consistent, daily dosing is important for maintaining stable thyroid hormone levels.

---

Q: What is the active ingredient in L-Thyroxin Henning 75 and how does it work?

The active ingredient in L-Thyroxin Henning 75 is levothyroxine sodium, which is a synthetic version of the naturally occurring thyroid hormone, thyroxine (T4). This synthetic hormone acts to replace the deficient hormone, helping to normalize metabolic processes when the thyroid gland is underactive.

---

Q: Are there any diseases that would prevent me from taking L-Thyroxin Henning 75?

Regulatory documents list several conditions where this medicine should not be taken, including an untreated hyperthyroidism (overactive thyroid) or untreated adrenal insufficiency. It should also not be used if a patient has recently had a heart attack. An individual's health status should be assessed by a physician before this medication is prescribed.

---

Q: What should I do if my dose of L-Thyroxin Henning 75 is too high?

If the dose is too high, it can lead to symptoms similar to an overactive thyroid, such as palpitations (feeling your heart pound) or tremors (shaking). Official information states that if signs of overdose occur, the treating physician may adjust the dose, potentially by reducing the daily amount or recommending a temporary interruption of the treatment. The correct dosage is then re-established based on close monitoring.

Official Storage and Disposal Requirements

Storage of L-Thyroxin Henning 75 tablets is strictly governed by regulatory labeling to maintain potency, which is sensitive to environmental factors. The medicine must be stored at or below 25, C and protected from light and moisture. Tablets should remain in their original packaging, and storage in high-heat or high-humidity environments, such as bathrooms, is prohibited.

To ensure safety, the product must be kept out of the sight and reach of children at all times.

Do not use the medicine past the labeled expiry date. Official disposal instructions require that the unused or expired product not be disposed of in household rubbish or wastewater. Instead, it must be returned to a pharmacy or designated collection point, following local pharmaceutical waste regulations to avoid environmental contamination.